Live Sessions

2021 AD/PD™ Virtual Conference

15:00 - 15:20 LIVE: PRE CONFERENCE SYMPOSIUM ON PROTECTIVE EFFECTS OF INSULIN AND INCRETINS IN AD/PD 01 JOIN
15:20 - 17:30 LIVE: PRE CONFERENCE SYMPOSIUM ON COMMON FEATURES OF NEURODEGENERATIVE DISEASE: EXPLORING THE BRAIN-EYE CONNECTION AND BEYOND JOIN
16:40 -17:00 LIVE: PRE CONFERENCE SYMPOSIUM ON PROTECTIVE EFFECTS OF INSULIN AND INCRETINS IN AD/PD 02 JOIN
18:00 - 18:20 LIVE: PRE CONFERENCE SYMPOSIUM ON PROTECTIVE EFFECTS OF INSULIN AND INCRETINS IN AD/PD 03 JOIN
15:00 - 15:30 LIVE DISCUSSION - CONGOPHILIC AMYLOID ANGIOPATHY (CAA)  VASCULAR DEMENTIA JOIN
15:00 - 15:30 LIVE DISCUSSION - MRI 1 JOIN
15:00 - 15:30 LIVE DISCUSSION - NEUROPATHOLOGY IN AD  LBD AND OTHER DEMENTIA JOIN
15:00 - 15:30 LIVE DISCUSSION - VIRUS IMPACT ON NEURODEGENERATIVE DISEASES  HERPES SIMPLEX VIRUS  COVID-19 JOIN
15:00 - 15:30 Biomarkers in Alzheimer’s Disease Diagnostics: Moving Toward Earlier Diagnosis - SUPPORTED BY Biogen JOIN
16:00 - 16:30 LIVE DISCUSSION - CHOLINERGIC MECHANISMS IN AD AND PD JOIN
16:00 - 16:30 LIVE DISCUSSION - IMAGING AND FLUID BIOMARKERS JOIN
16:00 - 16:30 LIVE DISCUSSION - AUTOPHAGY JOIN
16:00 - 16:30 LIVE DISCUSSION - ABETA STRUCTURE   TOXICITY  AND NEURODEGENERATION JOIN
16:00 - 16:30 MEET THE PROFESSOR - GUOJUN BU JOIN
17:00 - 17:30 LIVE DISCUSSION - BLOOD-BRAIN BARRIER  VASCULAR DAMAGE IN DEMENTIA JOIN
17:00 - 17:30 LIVE DISCUSSION - TRANSLATIONAL TREATMENT STRATEGIES 1 JOIN
17:00 - 17:30 LIVE DISCUSSION - FLUID BIOMARKERS 1 JOIN
17:00 - 17:30 LIVE DISCUSSION - DISEASE MODELLING WITH HUMAN CELLS -TREATMENT STRATEGIES JOIN
17:00 - 17:30 LIVE DISCUSSION - ABETA TARGETING THERAPIES IN AD 1 JOIN
17:00 - 17:30 LIVE DISCUSSION - BACE-1  PRESENILIN  GAMMA-SECRETASE AND APP PROCESSING JOIN
18:00 -19:00 FORUM ON IMPACT OF COVID-19 ON NEURODEGENERATIVE DISEASES JOIN
19:30 - 20:30 FORUM ON APPLICATIONS OF NEUROPSYCHOLOGY  PET  MRI  EEG  PLASMA AND CSF FOR DIAGNOSIS AND ASSESSMENT OF TREATMENT EFFECTS JOIN
Untitled Document
14:00 -15:30 The early diagnosis of Alzheimer’s disease: discovering complex clinical and pathological features - SUPPORTED BY Biogen JOIN
15:00 - 16:00 MEET THE PROFESSOR - RUDOLPH TANZI JOIN
15:30 - 16:00 LIVE DISCUSSION - TAU-TARGETED TREATMENT STRATEGIES JOIN
15:30 - 16:00 LIVE DISCUSSION - TREM2  MICROGLIA JOIN
15:30 - 16:00 LIVE DISCUSSION - TREATMENT STRATEGIES FOR PD AND DLB JOIN
15:30 - 16:00 LIVE DISCUSSION - AD DIAGNOSIS  EARLY PHASE AD  CLINICAL TRIALS (1) JOIN
16:30 - 17:00 Digital Cognitive Phenotyping in Neurodegenerative Disease: Impact of Digital on Neurology Practice - SUPPORTED BY nQ Medical JOIN
16:30 - 17:00 LIVE DISCUSSION - IMAGING AND BIOMARKERS IN PD  LBD JOIN
16:30 - 17:00 LIVE DISCUSSION - SYNAPTIC DAMAGE AND NEURONAL PLASTICITY JOIN
16:30 - 17:00 LIVE DISCUSSION - ALPHA-SYNUCLEIN AND DISEASE MECHANISMS (1) JOIN
16:30 - 17:00 LIVE DISCUSSION - TDP-43 IN ALS AND FTD JOIN
17:30 - 18:00 LIVE DISCUSSION - GENETICS OF NEURODEGENERATION 1 JOIN
17:30 - 18:00 LIVE DISCUSSION - TAU PATHOLOGY AND THERAPEUTIC STRATEGIES 1 JOIN
17:30 - 18:00 LIVE DISCUSSION - TREM2 AND TREM 1 (2) JOIN
17:30 - 18:00 LIVE DISCUSSION - C9ORF72 AND PROGRANULIN IN ALS AND FTD JOIN
17:30 - 18:00 LIVE DISCUSSION - ORGANOIDS AND ANIMAL MODELS IN AD  PD JOIN
18:30 - 19:30 FORUM ON PHASE I-II CLINICAL TRIALS IN ALZHEIMER’S DISEASE JOIN
10:00 -12:10 Using single cell and spatial technologies to untangle the complexities of neurodegenerative disease - SUPPORTED BY 10x Genomics JOIN
12:00 - 13:00 Parkinson’s. Time for meaningful change: looking back at symptomatic therapy and moving towards disease modification - SUPPORTED BY Roche JOIN
14:00 - 15:00 LIVE PANEL: Alzheimer’s disease perspectives from around the world - SUPPORTED BY Roche JOIN
15:30 - 16:00 LIVE DISCUSSION - AD ANIMAL MODELS AND MECHANISTIC ASPECTS (1) JOIN
15:30 - 16:00 LIVE DISCUSSION - AMYLOID AND TAU PET IMAGING JOIN
15:30 - 16:00 LIVE DISCUSSION - RNA JOIN
15:30 -16:00 LIVE DISCUSSION - AD DIAGNOSIS  EARLY PHASE AD  CLINICAL TRIALS (2) JOIN
16:00 -17:00 Gamma sensory stimulation  a novel AD therapeutic intervention: initial safety  efficacy and biomarker changes from two prospective clinical studies - SUPPORTED BY Cognito Therapeutics JOIN
16:30 -17:00 LIVE DISCUSSION - TAU PROPAGATION AND CELLULAR INTERACTIONS JOIN
16:30 -17:00 LIVE DISCUSSION - METABOLIC PATTERNS AND CHANGES IN AD AND LBD JOIN
16:30 -17:00 MEET THE PROFESSOR - ANGELA GENGE JOIN
16:30 -17:00 MEET THE PROFESSOR - CHRISTIAN HAAS JOIN
16:30 -17:00 LIVE DISCUSSION - AMYLOID  TAU AND SYNAPSE PET IMAGING JOIN
16:30 -17:00 LIVE DISCUSSION - GENETICS OF NEURODEGENERATION 2 JOIN
16:30 -17:00 LIVE DISCUSSION - MOLECULAR MECHANISMS IN PROTEINOPATHY JOIN
17:30 - 18:00 LIVE DISCUSSION - NEUROINFLAMMATION  MICROGLIA AND ASTROCYTES JOIN
17:30 - 18:00 LIVE DISCUSSION - MRI 2 JOIN
17:30 - 18:00 LIVE DISCUSSION - COGNITIVE DYSFUNCTIONS  PATHOLOGY AND TREATMENT APPROACHES IN PD  HD JOIN
17:30 - 18:00 LIVE DISCUSSION - PATHWAYS AND TARGETS IN MODELS OF SEEDED AGGREGATION JOIN
17:30 - 18:00 LIVE DISCUSSION - BIOMARKERS  IMAGING IN AD  PD AND LBD JOIN
18:30 -19:30 FORUM ON TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III -  RECENT UPDATES JOIN
Print Friendly, PDF & Email